Integrin alpha L beta 2

Integrin alpha L beta 2

Integrin alpha L beta 2 분자 정보

Molecule Name
Integrin alpha-L/beta-2 (LFA-1)
분자 별명
Integrin alpha L beta 2,ITGAL&ITGB2
Drug Development Progress
임상 약물 수1
시판 약물 수1
최고 연구 개발 단계Approved
표적 별명
Lymphocyte Function-Associated Antigen-1
분자 배경
Integrin alpha-L beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. Integrin alpha L beta 2 is also a receptor for F11R (By similarity). Involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes. Contributes to natural killer cell cytotoxicity. Involved in leukocyte adhesion and transmigration of leukocytes including T-cells and neutrophils. Required for generation of common lymphoid progenitor cells in bone marrow, indicating the role in lymphopoiesis. Integrin alpha L beta 2 in association with ICAM3, contributes to apoptotic neutrophil phagocytosis by macrophages.

Integrin alpha L beta 2 제품 목록

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

임상 약물 정보

영어 이름연구 코드연구 개발 단계회사적응증임상 시험
Alintegimod7HP349; 7-HP-349; 7HP-349Phase 2 Clinical7 Hills Pharma LLC
Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Chagas Disease; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Influenza, Human; Kidney Neoplasms; Lymphoma; Melanoma; Mesothelioma; Mismatch Repair Deficient Cancer; Neoplasm Metastasis; Neoplasms; Skin Neoplasms; Solid tumours; Tuberculosis
상세

시판 약물 정보

영어 이름연구 코드연구 개발 단계회사가장 빠른 브랜드 이름가장 빠른 승인 국가가장 빠른 적응증가장 빠른 승인 회사가장 빠른 승인 날짜적응증임상 시험
LifitegrastSHP-606; SAR-1119; SAR-1118; SPD-606; OJL-332ApprovedShire Development LlcXiidra, 朗悦明United StatesDry Eye SyndromesBausch And Lomb Inc2016-07-11
Conjunctivitis, Allergic; Diabetic macular oedema; Dry Eye Syndromes; Graft vs Host Disease; Keratoconjunctivitis Sicca; Xerophthalmia
상세